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Ewing sarcoma (ES) is the second most common bone tumor affecting primarily adoles-
cents and young adults. Despite recent advances in biological understanding, intensifica-
tion of chemotherapeutic treatments, and progress in local control with surgery and/or
radiation therapy, patients with metastatic or recurrent ES continue to have a dismal prog-
nosis with less than 20% overall survival. All ES is likely metastatic at diagnosis although
our methods of detection and classification may not account for this. Progressive disease
may arise via a combination of: (1) selection of chemotherapy-resistant clones in primary
tumor, (2) signaling from bone or lung microenvironments that may attract tumor cells to
distant locations, and/or (3) genetic changes within the ES cells themselves due to DNA-
damaging chemotherapeutic agents or other “hits.” These possibilities and the evidence
base to support them are explored.
Keywords: Ewing sarcoma, metastatic
INTRODUCTION
Ewing sarcoma (ES) is the second most common malignant bone
tumor in adolescents and young adults, leading to more than 200
cases of cancer in the United States per year (SEER). Evidence of
metastatic disease at diagnosis is the most clinically relevant prog-
nostic factor, affecting ∼25% of patients (Bernstein et al., 2006).
Despite recent advances in biological understanding, intensifica-
tion of chemotherapeutic treatments, and progress in local control
with surgery and/or radiation therapy, patients with metastatic or
recurrent ES continue to have a dismal prognosis with less than
20% overall survival.
Nearly every case of ES harbors a translocation of the EWSR1
gene, found on chromosome 22, with a member of the ETS family
on chromosomes 11, 21, or others. The classic ES translocation,
t(11:22)(q24;q12), creates the EWS–FLI1 fusion oncogene found
in around 85% of ES tumors. Other fusion partners have also been
described and account for the remaining 15% (Turc-Carel et al.,
1988;Delattre et al., 1992). TheEWS–FLI1oncogene influences the
gene expression profile of tumor cells, directly or indirectly, dri-
ving aberrant expression of over 1000 genes (Smith et al., 2006).
Interestingly, EWS–FLI1 expression is associated with activation
of some genes and repression of others, illustrating the complexity
of cellular response to this oncogenic transcription factor (May
et al., 1993).
The ES translocation is thought to be the primary mecha-
nism for tumorigenesis, but the heterogeneous biology found
in the tumors of patients with ES suggests that additional mol-
ecular mechanisms are also involved (Toomey et al., 2010).
Castillero-Trejo et al. (2005) using murine primary bone derived
cells (mPBDC), have shown that serial passage of retrovirally
transduced EWS–FLI1 mPBDCs produced tumors efficiently only
in later-passage cells (> passage 15). In addition, Lessnick et al.
(2002) established human primary fibroblast cell lines express-
ing the EWS–FLI1 fusion protein that underwent p53 mediated
growth arrest showing that for tumor formation to proceed, there
is likely a multistep process including the acquisition of other
genetic changes (Lessnick et al., 2002). This research supports
that the EWS–FLI1 translocation is an initiating event in sarco-
magenesis, but that other biological processes are required for full
tumorigenesis to occur (Lessnick et al., 2002; Castillero-Trejo et al.,
2005).
Ewing sarcoma cells spread hematogenously to distant sites.
Despite negative imaging studies andbonemarrowbiopsies,nearly
all ES is likely micro-metastatic at diagnosis. Why then are clini-
cally detectable metastases such an important prognostic factor?
Perhaps tumor cells have differing potentials to grow and develop
at distant sites determined by therapy selective pressures, micro-
environmental signals, and changes that are intrinsic to the tumor
cell’s genes. These metastatic clones may undergo genetic changes
that allow them to react differently to chemotherapeutic agents as
well as signals in the microenvironment (of lung or bone) lead-
ing to a more aggressive, resistant phenotype. Many questions
remain regarding the presence of ES clones that may lead to occult
metastatic deposits and subsequently to recurrence of disease after
completion of therapy. Are all ES metastatic clones similar or
are they a heterogeneous population of rogues of varying clinical
threat? This paper serves to review the current clinical knowledge
about metastatic ES, to highlight current areas of research regard-
ing the molecular pathways that influence ES metastasis, and to
underscore questions that persist at this time.
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To survey the recently published literature in a comprehen-
sive fashion, searches for “ES metastasis” and “metastatic ES”were
performed via the PUBMED database. Results showed 586 arti-
cles that were published after 1999 on this topic. Abstracts were
briefly scanned for relevance, and selected papers were reviewed
in full. Original supporting data (some dated prior to 2000) were
also used for the current review, based on the bibliography of the
papers found.
METASTATIC EWING SARCOMA: THE CLINICAL
PERSPECTIVE
Currently,metastatic disease is clinically defined by the presence of
a ES specific translocation in the tissue biopsy of at least one tumor
site (primary site) plus the presence of characteristic lesions (by
imaging) in bones, lungs, or malignant cells identified in a staging
bone marrow aspirate or biopsy. If diagnostic imaging is incon-
clusive for bone or lung sites, tissue biopsy may be undertaken
to prove metastasis. Bone marrow is typically considered nega-
tive for metastatic disease if the cells present are morphologically
hematopoietic in origin; peripheral blood is never clinically tested
for ES cells.While these parameters clinically definemetastatic dis-
ease and identify a high-risk sub-population of ES patients, they
likely do not completely quantify a patient’s burden of disease. Nor
do such tests give us information about the genetic changes in a
particular patient’s ES tumor cells.
Approximately 25% of patients will present with metastatic
disease, primarily with metastasis in the lungs, bony sites, and/or
bone marrow. As with most cancers, the presence of metastasis
is an important predictor of outcome. Patients with metastatic
ES have a 5-year relapse free survival of ∼30% (versus localized
disease= 61.3%, p< 0.001; Cotterill et al., 2000). Patients with
metastatic disease have a statistically significant proportion of
larger primary tumors (>8 cm) than patients without metastatic
disease (76.8 versus 54.3%, p< 0.00001) suggesting that primary
tumor size may correlate with metastasis (Rodriguez-Galindo
et al., 2008; Lee et al., 2010). On the other hand, some patients
who present with small primary tumors do relapse with distant
metastasis, indicating the propensity of ES for dissemination. In
terms of outcomes, patients with primary pulmonary metastasis
fare better than their counterparts with bone or bone marrow
disease (5 year EFS 29–52%) signifying that not all metastasis are
equal (Paulussen et al., 1998).
The approach to treating those with metastatic disease involves
systemic chemotherapy and local control of the primary site of
disease. With regard to systemic therapy, there have been a vari-
ety of trials attempting to optimize a chemotherapeutic regimen
specifically for patients with metastatic disease. These studies
have investigated more intensive, time-compressed, and high-dose
chemotherapy regimens, yet there has beenminimal improvement
in survival of patients with metastasis at presentation (Grier et al.,
2003; Granowetter et al., 2009; Huang and Lucas, 2011) First-line
agents are the same as for clinically localized disease (vincristine,
doxorubicin, cyclophosphamide, ifosfamide, and etoposide), but
there has been interest over the last decade in the use of camp-
tothecin agents (such as topotecan and irinotecan) for metastatic
disease (Wagner, 2011). The current front line Children’s Oncol-
ogy Group (COG) trial randomizes patients with localized ES
to receive topotecan in combination with cyclophosphamide to
attempt to improve survival rates, as this combination has shown
promise in patients with relapsed or refractory disease.
Despite systemic chemotherapy and good local control modal-
ities, even patients with clinically localized ES have a high-risk
of relapse at distant sites, giving rise to the hypothesis that
micrometastasis is almost universally present but undetected at
initial diagnosis. Reports have shown that 25–30%of patients with
clinically localized ES have detectable tumor cells in the periph-
eral blood or bone marrow by polymerase chain reaction (PCR;
West et al., 1997). The question then arises as to whether these
metastatic cells are clinically nefarious clones or rogues present-
ing a limited clinical threat. No data has been reported regarding
detectable tumor cells at diagnosis for patients with metastatic
disease, but one can hypothesize that it would be at least equiva-
lent to if not higher than levels seen in localized ES. Further studies
using peripheral blood PCR and/or flow cytometry in themetasta-
tic population would be of interest as the nature of the clones in
patients with clinically metastatic disease may differ from those
that are detected peripherally in cases of clinically isolated disease.
Perhaps comparative assessment of both primary and metastatic
sites at diagnosis may also add to this body of knowledge. Other,
smaller studies have suggested that detection of such EWS fusion
oncogene transcripts in the blood or marrow after completion of
therapy may portend relapse (Avigad et al., 2004). Again, are all
metastatic clones of the same clinical threat?
Ewing sarcoma relapse usually presentswithin 5 years following
intensive multi-agent chemotherapy and aggressive local control
measures (Stahl et al., 2011). The predominant type of relapse
in patients with initial metastatic disease is systemic (defined as
distant recurrence only) with 73% of patients presenting almost
evenly with pulmonary, bone, ormultisystem recurrent sites (Stahl
et al., 2011). The median survival time after a first recurrence is
9months, and the 5-year overall survival is 12% for recurrent
ES overall (Leavey et al., 2008). In recent data from the COG,
the median time to recurrence in patients with metastatic disease
at diagnosis is slightly earlier (∼1 year; Leavey et al., 2008). Late
recurrence, defined as greater than 2 years after initial diagnosis,
is associated with a better prognosis (currently greater than 25%
overall survival) whereas early recurrence portends a grave prog-
nosis (OS= 7–10%; Huang and Lucas, 2011). Stahl et al. (2011)
have corroborated that patients with initially clinically localized
disease relapsed significantly later than those with metastatic dis-
ease at diagnosis (434 versus 563 days, p< 0.001). In addition, the
patients that relapsed earlier had a significantly worse outcome
(OS 0–2 years= 0.07, 2–3 years= 0.27,>3 years= 0.30, p< 0.001;
Stahl et al., 2011).Overall, the data suggests thatmetastatic patients
are more likely to relapse early with systemic disease and have a
worse prognosis. This leads to the hypothesis that either tumor-
related OR patient-related factors may lead to these ES clone’s
ability to evade destruction or removal during treatment. Disease
that is cytoreduced into an initial state of subclinical tumor bur-
den,but not fully eradicated,necessarily harbors resistant clones of
ES. Chemotherapy provides both selective pressure favoring such
clones as well as additional DNA damage able to induce genetic
alterations that may generate new resistant clones. Early clinical
recurrence implies that either the clones were resistant enough to
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grow during therapy or aggressive enough to rebound rapidly after
therapy-suppression is lifted.
THE TUMOR MICROENVIRONMENT
The continued poor prognosis for patients with metastatic ES
questions the possible need for distinctive treatment strategies
designed specifically to preventmetastasis from the primary tumor
site and to target and eradicate known or latent metastatic dis-
ease (Riggi and Stamenkovic, 2007). Research has focused both
on understanding what triggers dissemination as well as what fac-
tors support tumor cell survival and proliferation in ectopic sites.
ES cells have a propensity to metastasize to the lung, bone, and
bone marrow (Arndt and Crist, 1999) suggesting an important
role of tumor cell microenvironment that may direct this tissue-
specific metastasis (Kerbel, 1995; Mundy, 2002). In recent years,
several labs have focused their efforts on understanding the con-
tribution of metastatic sites in attracting ES cells and supporting
their growth. To prevent ES metastasis, an understanding of these
unique tumor microenvironment and host–tumor interactions
may offer new therapeutic targets.
Ewing sarcoma usually arises from bone, but can also metasta-
size to distant bones. Thebone is a rich repository of growth factors
including stem cell factor (SCF, the ligand for c-kit receptor), basic
fibroblast growth factor (b-FGF), platelet derived growth factor
(PDGF), and transforming growth factor-β (TGF-β), therefore
providing chemo-attractants for metastatic disease and a favor-
able environment for metastatic growth of many types of tumors
(Mundy, 2002; Bussard et al., 2008). For example, metastatic sites
highly express SCF in the bone marrow stromal cells (BMSCs),
osteoblasts, and endothelial cells. Landuzzi et al. (2000) noted the
presence of substantial surface c-kit receptors in six ES cell lines;
transmembrane SCF was also found on five of the six cell lines.
Exposure of these ES cell lines to exogenous SCF caused down-
regulation of its receptor, decreased chemoattraction of ES cell
lines to SCF, and significantly reduced metastasis to lungs and
other extra-pulmonary organs in a metastatic xenograft model.
These data suggest that SCF expressed in potential metastatic sites
may serve a chemoattractant role and that the c-kit receptor/SCF
interaction is a potential target for decreasing ES metastasis
(Landuzzi et al., 2000).
Fibroblast growth factor produced by BMSCs may promote
a metastatic phenotype in ES tumors by increasing cell motility.
Conditioned medium from BMSCs was shown to increase motil-
ity in human ES cell lines, specifically through activation of FGF
receptor-1 (FGFR-1) by b-FGF and its downstream signaling cas-
cade, phosphatidyl inositol 3 kinase (PI3K)–Rac-1 (Kamura et al.,
2010). Receptors for FGF and PDGF are well-characterized and
small molecule inhibitors against these catalytic receptors may
provide a therapeutic option in ES.
Lyn, a member of the Src family of kinases, is a known regulator
of tumor cell proliferation, adhesion, motility, and invasion. Tar-
geting Lyn using a small interfering RNA (siRNA) or the small
molecule inhibitor AP23994 resulted in suppression of tumor
growth, decreased bony lysis due to tumor cells, and significantly
fewer lung metastases in vivo (in athymic nude mice injected with
TC71 human ES tumor cell lines; Guan et al., 2008). Here EWS–
FLI1 was shown to upregulate Lyn expression allowing increased
bony lysis. Such lysis creates space for tumor growth, and provides
easier access for tumor cells to the bone stroma where they may
enter the circulation and metastasize to the lung. This data sug-
gests that targeting Lyn upregulation may decrease the propensity
of ES cells to metastasize.
Finally, ezrin, a membrane–cytoskeleton linking protein, has
an effect on the development of metastasis in osteosarcoma and
rhabdomyosarcoma (Khanna et al., 2004; Yu et al., 2004). Krish-
nan et al. (2006) have shown that this is true for ES as well. In
normal cells, ezrin mediates signal transduction and cell to cell
interactions, and promotes growth. Phosphorylation at threonine
567 (T567) of ezrin is essential for ezrin-mediated transduction
of growth signals; mutation at this site, leading to absence of
phosphorylation at T567 (so called ezrinT567A mutants), causes
down-regulation of growth via the AKT/mTOR (mammalian tar-
get of rapamycin) pathway. Krishnan et al. (2006) have shown
that ES cell lines (both previously established cell lines and pri-
mary cell lines from patient tumor samples) have high levels of
ezrin expression, and ezrinT567Amutantsmaintain a significantly
slower growth rate than those with wild type ezrin expression
due to increased apoptosis. These data lend credence to ezrin’s
import in primary disease. In addition, injection of ezrinT567A
mutant cells into mice produced fewer experimental metastases
(2/30 mice developed metastasis) than mice injected with wild
type ezrin (8/10 mice) showing that ezrin may also have a role
in development and growth of metastasis in ES. Manipulation of
the ezrin pathway may be explored in the future as a means to
decrease the development of metastatic disease in ES (Krishnan
et al., 2006).
METASTATIC DISEASE, INSTABILITY OF THE CLONE
As a tumor grows and metastasizes, its genome can continue to
adapt allowing for creation of resistant clones that evade con-
ventional therapies. Newer technologies, such as copy number
analysis, rendering more detailed analysis of the genome than
is possible with traditional cytogenetics, have been used to also
look at genomic imbalances beyond translocation status in these
tumors. As cancer genomes become more unstable, the number of
copy number aberrations (CNA) increases (Jahromi et al., 2011).
Copy number analysis of primary tumors may be a way to iden-
tify tumors that are at higher risk of metastasis or relapse than
others. Several other tumor types have copy number changes that
are being used to risk stratify therapy for patients (e.g., neuroblas-
toma; Attiyeh et al., 2005), but this is currently not possible for ES
due to its rarity and challenge of obtaining a large enough cohort
to study. Researchers continue to analyze genomic changes in ES
samples (Armengol et al., 1997; Tarkkanen et al., 1999; Brisset
et al., 2001; Ozaki et al., 2001; Savola et al., 2009), but the results
have been discordant, possibly due to the small samples sizes used
and/or the variable biology of the disease coupled with a lack of
detailed clinical phenotyping.
In the late 1990s to early 2000s, several researchers described
chromosomal gain in ES tumor samples – most commonly tri-
somy 1q [due to derivative chromosome (1:16)], trisomy 8, and
trisomy 12 in 25, 35, and 25% of samples respectively (Armen-
gol et al., 1997; Tarkkanen et al., 1999). The literature supports
that 63–87% of ES tumor samples have CNAs detected by CGH
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(Armengol et al., 1997; Tarkkanen et al., 1999; Brisset et al., 2001;
Ozaki et al., 2001; Savola et al., 2009). The most common of these
CNAs have been analyzed for possible prognostic capacity, but
the results have been varied. Many groups found no statistically
significant changes in event-free survival or overall survival in ES
based on CNAs (Armengol et al., 1997; Tarkkanen et al., 1999;
Ozaki et al., 2001). However, two different groups found that the
number of aberrations did significantly predict patient survival.
Ozaki et al. (2001) showed in 48 patients that tumors with lower
CNAs (less than five) were significantly associated with improved
survival (p = 0.009). In addition, Savola et al. (2009) reported that
tumors with higher numbers of CNA (≥3) faired significantly
worse in terms of OS (p = 0.030) and EFS (p = 0.049) than those
with fewer CNAs. The findings to date are correlative in nature and
require experimental testing to demonstrate whether CNA’s reflect
tumor age, behavioral attributes, and both. Currently, there is not
a particular aberration or combination of changes being used to
stratify patients for therapy.
The average number of CNAs in ES tumors varies in the
literature. The most recent data using Agilent’s 44K oligoarray
platform included 0–26 aberrations per tumor with a mean of 7.2
(Savola et al., 2009). Older reports, using various CGH techniques,
reported on average two aberrations per tumor (range 1.14–3.6;
Armengol et al., 1997; Tarkkanen et al., 1999; Brisset et al., 2001;
Ozaki et al., 2001). Much of this variation may be due to the sam-
ples and techniques available for CGH at the time the data were
collected. Mean copy number changes per tumor in other sarco-
mas such as osteosarcoma, malignant fibrous histiocytoma, and
chondrosarcoma have been reported around 11, 6, and 6 respec-
tively (Tarkkanen et al., 1995; Larramendy et al., 1997a,b). In ES,
copy number changes were low in any given tumor sample lend-
ing credence to the primary translocation in ES being a single
major genetic hit of great import in development and mainte-
nance of tumors. This supports studies on cultured human ES
cells in which knockdown of EWS–FLI expression was shown to
be sufficient to reverse transformation and tumorigenic properties
(May et al., 1993). As stated earlier, however, EWS–FLI1 expres-
sion is likely not the only genetic or epigenetic hit that is required
for development and maintenance of ES (Lessnick et al., 2002;
Castillero-Trejo et al., 2005). Hopefully, as the resolution of SNP
microarrays increases and next-generation sequencing is intro-
duced, more clinically relevant and cooperating CNAs may be
discovered in ES.
Numbers of CNA in metastatic versus localized ES have been
studied and have yielded inconclusive results. Brisset et al. (2001)
found no difference between the type or average number of CNAs
of primary tumor samples in patients who presented with metas-
tasis. However, Savola et al. (2009) reported thatmetastatic tumors
showed more CNA (mean 11.8) than primary tumors (mean 5.8).
Finally, samples from relapsed tumors had greater than three times
as many copy number changes as did the samples of primary
tumors (1.9 versus 4.4 per tumor sample; Armengol et al., 1997;
Tarkkanen et al., 1999). From these data, it can be hypothesized
that CNA appear with increased frequency as a tumor metasta-
sizes or recurs, and that resistant clones with unstable genomes
continue to gain genetic changes as such tumors progress. How-
ever, none of these studies have compared paired primary and
metastatic lesion samples, so the clonal relationship of primary to
metastatic tumors remains unknown in ES. Other tumor types,
such as pancreatic carcinoma, have features in their metastatic
deposits consistent with the parent clones, yet with the addition of
newly acquired lesions reflecting that metastatic clones branched
from the parent clone (Yachida et al., 2010). In patients with ES,
the use of CNA on samples from both local and metastatic tumors
may support such a mechanism and ultimately be an effective way
to measure “fitness” of a clone for metastasis.
CLOSING REMARKS
Ewing sarcoma is an aggressive cancer of bone that targets the
adolescent and young adult population. In its metastatic form,
survival remains poor despite an influx of knowledge regarding
tumor biology and intensification of therapy. Even if the disease
is localized at diagnosis (and particularly if it is not), there are an
unfortunate number of patients who will relapse; relapsed ES is
very difficult to cure. Progressive disease is believed to arise via a
combinationof selectionof chemotherapy-resistant clones, signal-
ing from bone or lung microenvironments that may attract tumor
cells to distant locations, and/or genetic changes within the ES
cells themselves. Intrinsic genetic changes within the ES cells, due
to a combination of therapy-related selection and DNA-damaging
chemotherapeutic agents, may allow the attraction and migration
of resistant ES clones to locations where they may thrive. As these
clones compete to survive by evading chemotherapy and respond-
ing to signal from metastatic sites, enhanced genomic instability
may favor their adaptation.While understanding the biology of the
primary tumor is of utmost importance, it is also critical to under-
stand genetic and epigenetic changes that are associated with the
metastatic state in order to effectively treat sarcoma patients with
systemic disease. Current advances in genetics and genomics pro-
vide new approaches to identify novel molecular markers that are
associatedwithmetastatic ES anddefine their clinical implications.
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